Simvastatin as add-on therapy to interferon beta-1a for relapsing-remitting multiple sclerosis (SIMCOMBIN study): a placebo-controlled randomised phase 4 trial
Publication year: 2011 Source: The Lancet Neurology, In Press, Corrected Proof, Available online 11 July 2011Per Soelberg, Sorensen , Jan, Lycke , Juha-Pekka, Erälinna , Astrid, Edland , Xingchen, Wu , … Background: Treatment of relapsing-remitting multiple sclerosis with interferon beta is only partly effective. We aimed to establish whether add-on of simvastatin, a statin with anti-inflammatory properties, improves this efficacy. Methods: We enrolled treatment-naive patients with relapsing-remitting multiple sclerosis in a multicentre, placebo-controlled, double-blind, randomised, parallel-group trial of simvastatin (80 mg daily) as add-on treatment to intramuscular interferon beta-1a (30 ?g weekly). After starting treatment with interferon beta, patients were randomly assigned (in computer-generated blocks of four patients) to simvastatin 80 mg per day or placebo for 1–3 years. Patients and treating and evaluating physicians were masked to treatment allocation. The primary outcome measure…
Sent from Feeddler RSS Reader
